Michael Diefenbeck M.D., Ph.D., founder of Scientific Consulting in Orthopaedic Surgery, has been appointed Chief Medical Officer (CMO) at BONESUPPORT AB. The company, focused on injectable bioceramic bone scaffolds, is based in Lund, Sweden.
Michael Diefenbeck New CMO of BONESUPPORT
1 min read Premium comments
#bonesupport#michaeldiefenbeck
According to the April 11, 2017 news release, “Dr. Diefenbeck…has worked for BONESUPPORT on a range of clinical projects related to CERAMENT as an independent clinical advisor. He is currently honorary consultant at Nuffield Orthopaedic Centre, Oxford University Hospitals. Dr. Diefenbeck studied medicine at Munich and was trained as an orthopaedic surgeon, specializing in trauma care and bone infections. He has 14 years’ clinical experience at different German hospitals (BG Unfallklinik Murnau, BG Kliniken Bergmannstrost Halle/Saale, University Hospital Jena and Schön Klinik Hamburg Eilbek). At University Hospital Jena he finished his Ph.D. in 2011 and has since been involved in surgical education and training programs for students. He is author of 24 Pub-med listed research articles.”
Dr Diefenbeck said: “I am excited to be joining BONESUPPORT at a particularly exciting time for the company. I look forward to working with the BONESUPPORT team.”
Richard Davies, CEO of BONESUPPORT, said: “We are pleased to welcome Michael to the BONESUPPORT team. I have no doubt that his extensive medical experience in the orthopaedics field and his knowledge of our CERAMENT platform that he will be a real asset to BONESUPPORT as we look to grow our business and deliver value to all of our stakeholders.”
Dr. Diefenbeck told OTW, “Now that I am in the post, I look forward to helping shape the future development of BONESUPPORT, as the company continues to develop and reinforce the clinical benefits its CERAMENT based products delivery.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.